Kusatsu/Shiga Japan – October 11, 2018 – Takara Bio Inc. (Takara Bio), announced today that our Cancer Genetic Testing Business conducted in Osaka University Hospital obtained a Laboratory Accreditation (LAP) certification approved by College of American Pathologist (CAP).


  For the purpose of cancer screening and therapy based on the genome information, cancer genome medicine is expected to be applicable in new diagnosis, therapeutic development and selection of effective drug. Takara Bio concluded a partnership agreement with Osaka University Hospital in the project of cancer genome medicine in August 2017, and a clinical sequencing lab has been established in Osaka University Hospital to perform the cancer genetic testing services. Also, Osaka University Hospital has been designated as a Core Base for Cancer Genome Medicine by the Ministry of Health, Labour and Welfare this past April, and started the advanced medical care related to cancer genetic testing on October 1. Takara Bio and Osaka University Hospital will cooperatively work on this project.


  CAP-LAP is a certification system of global clinical testing conducted by CAP. Given a solid evidence about accuracy assurance in the field of genetic testing using next generation sequence, the quality improvement for this testing in Osaka University Hospital is highly expected.



Applicable Standard


Registered Organization

Clinical sequencing lab, Osaka University Hospital

Registered Scope

Clinical testing using next generation sequence

Molecular pathology, Next generation sequencing

Registration Date

September 18, 2018

Registration Number


Review Organization

College of American Pathologist (CAP)